Recently, high levels of macrophage migration inhibitory factor (MIF) have been associated with tumor recurrence and poor survival, and MIF is now emerging as a promising anti-angiogenic target in glioblastoma [94,95,96,97]. This evidence concerns the gene MIF and glioblastoma.